All In MedTech

Device Trial Radar · NCT07949773

Peds Proton Therapy

Operational and Clinical Evaluation of the Treatment Planning Software and Oncology Information System for Pediatric Proton Therapy

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Oct 13, 2026

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 19, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to evaluate the clinical utilization and safety of RayStation 2025 and RayCare 2025 treatment planning software upgrades when used to support standard-of-care proton therapy delivery in patients deemed clinically appropriate for such therapy by their treating radiation oncologist.

Conditions

  • Radiation

Interventions

  • RayTracker and RayAdaptive Software AnalysisDevice

    Part of a not yet FDA-cleared software, the RaySearch treatment planning system and RayCare oncology information system. RayTracker enables longitudinal evaluation of treatment by recalculating dose on daily images and accumulating dose across fractions using deformable image registration, thereby providing an estimate of the cumulative delivered dose to targets and organs at risk. RayAdaptive uses daily treatment imaging (such as cone-beam CT (CBCT)) together with the planning CT to generate an updated representation of patient anatomy and recalculation of dose on the current patient anatomy, allowing clinicians to evaluate whether anatomical changes could meaningfully alter the planned dose distribution. These features are designed to be used in tandem. Their combined capabilities are intended to support clinical decision-making related to treatment monitoring and potential adaptation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of verification image assessments for each subject resulting in a clinical adaptive replanning decisionTime frame: up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.